Перейти к содержанию
TelegramInformer

The Lancet

@the_lancet Здоровье английский

All the latest articles published on Lancet Journal Discussion Group https://t.me/Medical_Professionals_Forum Contact us https://t.me/Contact_Updates_in_Medicine_Bot

Открыть в Telegram
Подписчики
18 234
24 часа
+4
7 дней
+44
30 дней
–
Средний охват поста
345
Просмотры поста через 24 часа
Вовлечённость
1,9 %
Охват ÷ подписчики (ERR)
Постов в день
5
В среднем за 30 дней
Упоминания
0
Другими каналами за 90 дней
Реакции на просмотры (ER)
0,12 %
(Реакции + репосты + комментарии) ÷ просмотры, 30 дней
В среднем на пост
Реакции
0
Репосты
0
Комментарии
0
Индекс цитирования
–
Другие каналы не цитировали его за 30 дней
Рекламные посты
0 %
0 из 36 постов за 30 дней помечены как реклама

Динамика подписчиков

Подписчиков у канала «The Lancet»: 18 234. Средний охват поста за сутки около 345, вовлечённость 1,9 %.

По дням, последние 30 дней
Дата Подписчики Изменение Посты Ср. просмотры поста
11 ноя 18 234 +4 4 382
10 ноя 18 230 +6 3 405
9 ноя 18 224 +7 8 429
8 ноя 18 217 +29 1 611
4 ноя 18 188 +245 0 –
4 окт 17 943 – 0 –

Просмотры по возрасту поста

Средние просмотры в каждом возрасте, посты за последние 30 дней.

1 ч
39
3 ч
149
6 ч
165
12 ч
250
24 ч
345
48 ч
417
3 дня
398

Когда публикует

Время по UTC. 36 постов за 90 дней.

Последние посты

  1. Открыть пост

    [Articles] Trevogrumab (anti-GDF8) with or without garetosmab (anti-activin A) for prevention of muscle loss during semaglutide-induced weight reduction in people with obesity (COURAGE): a two-part, phase 2, double-blind, placebo-controlled, randomised trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01953-7/fulltext?rss=yes This study establishes proof of concept for GDF8 inhibition by trevogrumab alone as a generally well tolerated strategy to preserve lean mass during GLP-1 receptor agonist-induced weight loss. Although the addition of ActA inhibition by garetosmab further improved body composition and weight loss, the combination did not have favourable safety an...

    215 просмотров
  2. Открыть пост

    [Articles] Infection and inflammation as risk factors for post-stroke cognitive impairment and dementia: a systematic review and meta-analysis https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(26)00581-X/fulltext?rss=yes Post-stroke infection is associated with increased risk of PSCID, with SVD potentially conferring increased susceptibility. Inflammatory biomarker associations suggest a role for BBB damage and immune activation. However, available evidence cannot distinguish an infection-specific effect in PSCID from infection-associated inflammation, stroke-induced sterile inflammation, or their combination.

    333 просмотров 2 Репосты
  3. Открыть пост

    [Comment] A digital intervention to strengthening parenting in Tanzania https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)02198-7/fulltext?rss=yes Preventing children's exposure to hardship, trauma, and abuse in childhood is a global public health priority. This exposure is associated with a substantial burden of disease and is one of the most important risk factors for experience and perpetration of violence against women, with all the entailed health consequences.1–3 Over recent years, research on and development of interventions to prevent child abuse and neglect through strengthening of parenting have intensified. Reviews show considerable success with some intervention...

    473 просмотров 1 Реакции
  4. Открыть пост

    [Review] Reframing disease elimination: an update from the Lancet Commission on chronic obstructive pulmonary disease https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01947-1/fulltext?rss=yes Chronic obstructive pulmonary disease (COPD) remains a leading cause of morbidity and mortality worldwide, with increasing global burden driven by population growth and ageing, persistent harmful exposures, and substantial health inequities. The Lancet Commission on COPD articulated an ambitious vision for disease elimination with prevention, early detection, and intervention. This Review revisits that vision, assesses progress since 2022, and calls for a broader commitment to lifelon...

    421 просмотров
  5. Открыть пост

    [Articles] A blended digital parenting intervention for the prevention of sexual violence, exploitative sex, and maltreatment of children at scale in Tanzania: a cluster-randomised, controlled trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01819-2/fulltext?rss=yes A low-cost blended digital parenting programme in countries such as Tanzania could simultaneously reduce childhood sexual violence (for girls) and maltreatment and sexual violence risk situations (for girls and boys).

    347 просмотров
  6. Открыть пост

    [Articles] National burden of lung cancer in Kazakhstan: a 10-year cohort study https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(26)00568-7/fulltext?rss=yes Our estimates reflect the escalating public health challenges in Kazakhstan. LC is primarily diagnosed in advanced stages, making preventive measures particularly important.

    384 просмотров 1 Реакции 1 Репосты
  7. Открыть пост

    [Articles] Two-step deep learning for candidemia prediction using time-series electronic health record data from the USA: a model development and validation study https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(26)00520-1/fulltext?rss=yes A two-step deep-learning framework integrating candidemia and mortality risk may support early identification of high-risk patients and facilitate timely empiric antifungal therapy. Prospective studies are warranted to confirm the findings.

    401 просмотров
  8. Открыть пост

    [Review] Targeting the PI3K/AKT/mTOR pathway in endocrine-resistant, hormone receptor-positive, HER2-negative, advanced breast cancer https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(26)00573-0/fulltext?rss=yes Combination treatment with endocrine therapy and cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors is the standard first-line treatment for hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, advanced/metastatic breast cancer. However, mechanisms of resistance to endocrine therapy plus CDK4/6 inhibitors, mostly classified as alterations involving activation of cell cycle mediators or alternative signalling axes such as the PI3K/AKT/mTOR...

    440 просмотров 1 Репосты
  9. Открыть пост

    [Articles] Efficacy and safety of efinopegdutide in adults with metabolic dysfunction-associated steatohepatitis and stage 2–3 fibrosis: a phase 2b, randomised, placebo-controlled study https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)02043-X/fulltext?rss=yes Treatment with efinopegdutide resulted in a significantly greater proportion of participants with MASH resolution without worsening of fibrosis compared with placebo. The 7 mg dose showed the most favourable benefit–risk profile, improving fibrosis by at least one stage without worsening steatohepatitis in approximately half of participants after 1 year of treatment. These findings support the potential utility of efi...

    502 просмотров 1 Репосты
  10. Открыть пост

    [Comment] Efinopegdutide: a step towards precision in MASH therapy? https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)02193-8/fulltext?rss=yes The global impact of metabolic dysfunction-associated steatohepatitis (MASH) across diverse populations is significant. MASH cirrhosis has become a leading indication for liver transplantation and a primary driver of hepatocellular carcinoma. Advanced MASH fibrosis is associated with increased all-cause mortality and a nearly two-times increased risk of extrahepatic malignancies.1

    432 просмотров 1 Репосты

Вопросы о канале «The Lancet»

Сколько подписчиков у канала «The Lancet»?

У канала «The Lancet» (@the_lancet) 18 234 подписчика на 12 ноября 2026 г.

Сколько человек видят пост в канале «The Lancet»?

Средний пост набирает около 350 просмотров за 24 часа, это примерно 2 % подписчиков (ERR).

О чём канал «The Lancet»?

Канал в категории «Здоровье», язык постов: английский. Описание канала: «All the latest articles published on Lancet Journal Discussion Group https://t.me/Medical_Professionals_Forum Contact us https://t.me/Contact_Updates_in_Medicine_Bot»

Какое место занимает канал «The Lancet»?

По числу подписчиков: №49 в категории «Здоровье», №1 202 среди каналов на языке «английский», №1 467 в мире.

Публикует ли канал «The Lancet» рекламу?

За последние 30 дней ни один из 36 постов не помечен как реклама (#ad, Sponsored, «Реклама»). Рекламу без пометки определить нельзя.

Статистика обновлена 5 минут назад.